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Abstract
Study Design: Prospective cohort study.
Objectives: To describe the rate of short-term complications following the posterior use of recombinant human bone mor-
phogenetic protein–2 (rhBMP-2) in cervical deformity (CD) surgery.
Methods: CD patients from 2013 to 2015 were enrolled in a prospective, multicenter database. Patients were divided into those
receiving rhBMP-2 (BMP) and no rhBMP-2 (NOBMP). The relationship between BMP use, demographic variables surgical vari-
ables, radiographic parameters and complications was evaluated.
Results: A total of 100 patients (47 BMP, 53 NOBMP) were included. Follow-up time averaged 7.6 months (range 3-12 months).
An average of 13.6mg of BMP was used per person with 1.49 mg per level. Compared with the NOBMP group, patients in the BMP
group were older (P¼ .03). BMP was more commonly used in patients that and had longer prior fusions (6.0 vs 2.5, P < .01). There
were no differences between groups with regards to a history of surgery, Charlson Comorbidity Index, estimated blood loss,
operation time, fusion levels, and surgical approach. The maintenance of radiographic parameters at 6-month follow-up was
similar. There were no differences in terms of total complication incidence, total complications per person, major complications
per person or any specific complication. Linear regression and Pearson correlation analysis did not reveal any strong r2 values
(r2 ¼ 0.09, 0.08, 0.06) between the use of BMP and complications (major or operative).
Conclusions: BMP use was not directly associated with an increased incidence of early complications in this prospective cohort
of operative adult CD patients. Its use was associated with increased number of levels instrumented and fused.
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Introduction
Recombinant human bone morphogenetic protein–2 (rhBMP-
2) was first approved in 2002 for use in anterior lumbar
interbody fusion (ALIF) surgery with a proprietary titanium
interbody cage.1 In subsequent years, rhBMP-2 has been used
off label in all areas of the spine, including the cervical, thor-
acic, and lumbar spine. In 2006, it was estimated that bone
morphogenetic protein (BMP) was used in 25% of all spinal
fusions2 and that 85% of this use was for off-label indica-
tions.3 RhBMP-2 has been an attractive alternative to the
traditional gold standard (autologous iliac crest bone graft
[ICBG]) because it results in equivalent or slightly higher rate
of radiographic fusion while avoiding donor site morbidity.4-6
This increase in fusion rates, however, has been accompanied
by persistent concerns about the possibility of increased
complications.7,8
Specific to the cervical fusions, the use of BMP in anterior
cervical fusions, in particular, has been shown to increase the
risk of wound infection, dysphagia and retropharyngeal
edema.9-12 The latter is a potentially life-threatening complica-
tion requiring emergent interventions such as intubation and
surgical reexploration.10 Recognition of this phenomenon led
to a statement by the US Food and Drug Administration (FDA)
recommending that practitioners avoid BMP use in the anterior
cervical spine.13
The use of BMP in the posterior cervical spine, however, has
been recently examined in several retrospective studies without
the airway complications reported with anterior use.14-18 These
studies have shown rates of nonunion ranging from 0% to
10.3% with the majority showing an improvement fusion rates
based on computed tomography imaging. Other authors, focus-
ing on posterior BMP use at the cervicothoracic junction, found
that the use of BMP did not result in a significantly different
rate of symptomatic non-union requiring reoperation.19
The existing literature on this topic is retrospective in
nature, narrowly focused on radiographic outcomes and lim-
ited to patients with degenerative pathology. The rate of com-
plications following BMP use in patients with cervical
deformity is unknown. We chose to focus cervical deformity
patients (as opposed to routine posterior cervical fusions)
because the use of BMP in these patients is attractive because
these patients are at high risk for pseudarthrosis. The risk of
pseudarthrosis is higher in these patients because they are
treated with long fusion constructs that frequently cross the
cervicothoracic (and sometimes the thoracolumbar) junction.
In addition, the instrumentation in this area is often thinner
and smaller; this fact, combined with alignment correction
can lead to higher rates of rod fractures and instrumentation
failure if fusion is not achieved.
The objective of this study was to identify the short-term
complications associated with BMP use in a prospective data-
base comprised of adult cervical deformity patients. We sought
to determine the impact of BMP use on short-term complica-
tions in adult cervical deformity surgery.
Methods
Subjects
This study was a retrospective review of a prospective multi-
center database of cervical deformity patients. Cervical defor-
mity was defined as one or more of the following criteria:
cervical kyphosis >10, cervical scoliosis >10, C2-7 sagittal
vertical axis (SVA) >4 cm, or horizontal gaze impairment
(chin-brow vertical angle >25). Eleven participating sites
in the United States contributed patients to the data set.
Patients were enrolled between January 2013 and October
2015. Institutional review board approval was obtained at all
participating centers.
Patients were enrolled if the following inclusion criteria
were met: age >18 years old, at least 1 posterior cervical sur-
gery (ie, posterior only approaches or combined anterior and
posterior surgery), full documentation of perioperative compli-
cations and a minimum 3 months of postoperative follow-up.
Patients with cancer, infection and patients who were pregnant
or planning to get pregnant during the study period were
excluded from the study. Patients were divided into 2 treatment
groups: those receiving rhBMP-2 (BMP) or no rhBMP-2
(NOBMP). All patients in the BMP group had BMP placed
posteriorly, none of the patients in this cohort received BMP
in anterior approaches.
Data Collection
Standardized data collection forms were used to collect demo-
graphic, surgical, radiographic, and complication data. Data
collection forms were completed at the perioperative time point
and at 3 months, 6 months, and 1 year postoperatively. Stand-
ing long-cassette radiographs were obtained preoperatively,
immediately after surgery, and at 6-month follow-up. The last
available time point was used for analysis of the radiographic
and complication data.
Demographic data collected included age, body mass index
(BMI), height, weight, gender, Charlson Comorbidities Index
(CCI), and smoking history. Surgical data included the surgical
approach, fusion levels, estimated blood loss (EBL), operation
time, and rhBMP-2 use.
Complications were categorized as cardiopulmonary com-
plications, dysphagia, dysphonia, electrolyte abnormalities,
gastrointestinal complications, infections, instrumentation-
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related complications, musculoskeletal complications, neurolo-
gical complications, operative complications, organ failure,
radiographic complications, renal complications, vascular
complications, wound complications, and other complications.
Complications were also labeled major or minor based on con-
sensus agreement of the study group surgeons. A complication
that prolonged hospitalization or adversely affected the recov-
ery of the patient was considered a major complication. A
complication that was noted in the medical records but did not
alter the patient’s recovery was considered a minor complica-
tion, as previously reported.20-22 Complications requiring revi-
sion surgery were also noted.
All spine radiographs were analyzed using validated soft-
ware (SpineView; ENSAMLaboratory of Biomechanics, Paris,
France) at a central location based on standard techniques.23,24
The following postoperative cervical radiographic parameters
were measured: cervical SVA (C2-C7 SVA: offset from the C2
plumb line and the posterosuperior corner of C7), C2-C7 lor-
dosis (Cobb angle between C2 inferior endplate and C7 inferior
endplate), fused cervical lordosis (Cobb angle between the
fused cervical levels), unfused cervical lordosis (Cobb angle
between the unfused cervical levels) and mismatch between T1
slope (TS) and C2-C7 angle (TS-CL).
Statistical Analysis
Descriptive, univariate analysis and multivariate regression
were all performed using SPSS (version 22.0, IBM Corp,
Armonk, NY, USA). Descriptive statistics were calculated for
all study variables. Univariate analyses were used to deter-
mine the differences of variables between BMP and NOBMP
groups. Regression analyses were performed to determine the
risk factors for complications. The multivariate analysis
included the following variables: age, gender, BMI, smoking
history, previous cervical surgery history, numbers of previ-
ous cervical surgery, numbers of previous anterior cervical
fusion, numbers of previous posterior cervical fusion, steroids
use or not, intensive care unit stay or not, posterior BMP dose,
number of posterior fusion levels, posterior BMP dose per
level. P values of less than .05 were considered significant.
The adjusted r2 statistic was used to assess the overall
explanatory ability of the linear models.
Results
Demographic Variables
A total of 100 patients with cervical deformity were enrolled in
the current study (53 BMP and 47 NOBMP). The mean age was
61.5 years. Follow-up averaged 7.6 months (3-12 months).
BMP patients were significantly older (63.62 vs 59.15 years,
P ¼ .038). but had similar BMI, CCI, current smoking status,
and past smoking history as NOBMP patients (Table 1).
Surgical Variables
The mean total rhBMP-2 dose for BMP patients was
13.58 mg (range: 1-60 mg). BMP patients had an average
Table 1. Comparison Between BMP and NOBMP Patients Regarding Demographic, Surgical, and Radiographic Variables.a
Variables NOBMP (n ¼ 47) BMP (n ¼ 53) Pb
Demographic variables
Age, y 59.15+ 10.18 63.62 + 10.99 .038
BMI, kg/m2 28.63+ 7.94 31.21 + 8.64 .141
Levels fused preoperatively 2.53+ 3.44 6.02 + 6.30 .002
Current smokers 6 (12.8) 2 (3.8) .114
Past smokers 15 (31.9) 11 (20.8) .181
Prior cervical surgery 21 (44.7) 27 (50.9) .207
Surgical variables
EBL, mL 948.64+ 1018.93 880.39 + 689.14 .697
Total posterior levels fused 8.30+ 4.92 9.60 + 3.40 .123
Operation time, min 356.94+ 194.90 304.12 + 125.25 .111
Posterior only approach 25 (53.2) 35 (66.0) .114
Anterior corpectomy 5 (10.6) 2 (3.8) .172
Posterior osteotomy 29 (61.7) 30 (56.6) .377
Postoperative pseudarthrosis 2 (4.3) 0 (0.0) .237
ICU stay 30 (63.8) 49 (92.5) <.001
Radiographic variables
Maintenance of C2-C7 lordosis, deg 1.73+ 13.17 0.24 + 9.79 .655
Maintenance of C2-C7 SVA, mm 0.18+ 9.56 1.44 +7.66 .698
Maintenance of unfused cervical lordosis, deg 2.33+ 4.46 0.75 + 4.03 .299
Maintenance of fused cervical lordosis, deg 1.40+ 7.57 0.59 + 9.80 .587
Abbreviations: BMP, patients receiving recombinant human bone morphogenetic protein–2 (rhBMP-2); NOBMP, patients not receiving rhBMP-2; BMI, body mass
index; EBL, estimated blood loss; ICU, intensive care unit; SVA, sagittal vertical axis.
aValues are presented as mean + standard deviation or n (%).
bBoldfaced P values indicate statistical significance.
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of 9.6 levels fused with a mean BMP dose of 1.49 mg/level
(range: 0.13-8.57).
EBL, total posterior fusion levels and operative time were
similar for BMP and NOBMP patients (Table 1). Surgical
approaches (posterior only or combined anterior and posterior),
anterior corpectomy, posterior osteotomy and postoperative
pseudarthrosis were also comparable between the two groups
(all P > .05, Table 1). Patients in the BMP and NOBMP cohort
had undergone prior cervical surgery at similar rates. BMP was
more commonly used in patients that had longer prior fusions
compared to NOBMP patients (6.02 vs 2.53 levels, P ¼ .002).
In addition, BMP patients were more likely to stay in the sur-
gical intensive care unit postoperatively (92.5% vs 63.8%,
P < .001). Although the intensive care unit length of stay was
recorded, the reason for this increased length (eg, prolonged
intubation) was unknown.
Radiographic Variables
The maintenance of postoperative radiographic parameters at
6-month follow-up was similar in BMP and NOBMP patients,
including C2-C7 SVA, C2-C7 lordosis, TS-CL, fused cervical
lordosis and unfused cervical lordosis (all P > .05, Table 1).
Complications
Five patients (1 BMP, 4 NOBMP) did not have any complica-
tions data recorded and were excluded from the complications
analysis. Complications in the remaining 95 patients were ana-
lyzed. In these remaining 95 patients (52 BMP, 43 NOBMP)
there were a total of 101 complications in 68 patients. 38
patients experienced at least 1 major complication and 30
patients had minor complications only (Table 2). 15 patients
had complications requiring reoperation.
There were no significant differences between BMP and
NOBMP patients with regard to any kind of complication inci-
dence, including total complications, complications per patient,
major complications per patient, minor complications per
patient, and each specific complication (Table 3). There were
also no differences between complication rates at 30 and
90 days after surgery.
In BMP patients, a linear regression analysis revealed no
relationship between rhBMP-2 dose and the number of total
complications, minor complications, complications requiring
re-operation, infections, neurological complications, dyspha-
gia, dysphonia, and instrumentation related complications
(Table 4). Linear regression also did not reveal any strong
relationships between BMP dose and posterior fusion levels,
major complications, and operative complications (r2 < 0.1
despite statistical significance, Table 4). Logistic regression
also showed neither total BMP dose nor BMP dose per level
could predict the total number of complications, major compli-
cations, or minor complications (Table 5). Finally, there were
no differences in clinical outcomes between the BMP and
NOBMP groups (Table 6).
Discussion and Conclusions
Our data demonstrates that BMP can be used in the operative
management of adult cervical deformity without an increase in
early complications (Table 3). The use of BMP did not result in
any increase in complications, including dysphagia, neurologic
complications, and wound complications. These findings sug-
gest that BMP may be safely used posteriorly in the setting of
cervical deformity.
Most existing literature examining posterior BMP use in
the cervical spine has focused on radiographic fusion as the
outcome.14,15,18,19,25 The majority of these studies report a
higher radiographic fusion rate with BMP, but there may not
be a substantial difference in clinically significant nonunion—
defined as pseudarthrosis requiring revision—between these
groups.18,19,25 This question of clinical significance is impor-
tant and is particularly relevant to the subject of BMP. The Yale
Open Data Access (YODA) Project, for example, found that
the use of BMP likely leads to an increased risk of complica-
tions.7 Indeed, their work suggested that although the use of
BMP results in marginally higher fusion rates, this may not be
clinically significant in the face of a higher costs, complication
rates and unchanged clinical outcomes. While the YODA proj-
ect focused on BMP use in the lumbar spine, it is important that
use of BMP in the cervical spine receive similar scrutiny that
focuses on outcomes beyond radiographic healing.
To that end, there has been little work performed examining
complication rates following BMP use in cervical spine sur-
gery.17,26 Xu et al17 found that the use of BMP posteriorly in
patients undergoing surgery for degenerative cervical condi-
tions did not lead to an increase in complication rates and led
to an increased rate of fusion based on computed tomography
imaging and radiographs. Interestingly, these authors also
noted an increased rate of neck pain in the BMP group.17 More
Table 2.Description of Complications by Complication Type (Sorted
by the Frequency of the Complication).
Total
Complications
(n ¼ 101), n (%)
Major
Complications
(n ¼ 51), n (%)
Minor
Complications
(n ¼ 50), n (%)
Neurological 24 (23.8) 13 (25.5) 11 (22.0)
Operative 23 (22.8) 18 (35.3) 5 (10.0)
Cardiopulmonary 12 (11.9) 9 (17.6) 3 (6.0)
Dysphagia 11 (10.9) 2 (3.9) 9 (18.0)
Infection 11 (10.9) 1 (2.0) 10 (20.0)
Radiographic 4 (4.0) 3 (5.9) 1 (2.0)
Instrumentation 4 (4.0) 2 (3.9) 2 (4.0)
Organ failure 2 (2.0) 2 (3.9) 0 (0.0)
Vascular 2 (2.0) 1 (2.0) 1 (2.0)
Dysphonia 2 (2.0) 0 (0.0) 2 (4.0)
Electrolyte 2 (2.0) 0 (0.0) 2 (4.0)
Gastrointestinal 2 (2.0) 0 (0.0) 2 (4.0)
Other 2 (2.0) 0 (0.0) 2 (4.0)
Musculoskeletal 0 (0.0) 0 (0.0) 0 (0.0)
Renal 0 (0.0) 0 (0.0) 0 (0.0)
Wound 0 (0.0) 0 (0.0) 0 (0.0)
Iyer et al 625
recently, Goode, et al26 performed a registry study examining a
large Claims and Encounters database.26 They reported that
patients receiving BMP were more likely to have a complica-
tion, undergo revision surgery and had a higher 30-day read-
mission rate. While Goode et al26 considered both anterior and
posterior BMP use in their analysis, their findings did not differ
substantially based on approach.
Both these studies, however, were retrospective studies
focused primarily on degenerative spine conditions. The cohort
in Xu et al,17 for example, was undergoing 5-level posterior
cervical fusions. That cohort is significantly different from the
patient population presented in our study. Patients with cervical
deformity frequently need longer fusions (9 levels or more) that
cross 1 or more spinal segments (occipotcervical and cervi-
cothoracic junctions). Prior studies have shown that patients
Table 3. Incidence of Complications in BMP and NOBMP Patients.
NOBMP (n ¼ 43) BMP (n ¼ 52)
P
Complications per








Total complications 1.35+ 1.36 58 (134.8) 1.17+ 1.37 61 (117.3) .534
Major complications 0.60+ 0.85 26 (60.4) 0.60+ 1.03 31 (59.6) .966
Minor complications 0.74+ 0.77 32 (74.4) 0.58+ 0.75 30 (57.7) .677
Complications—first 30 days postoperative
Total complications 0.95+ 1.23 41 (95.3) 0.75+ 1.06 39 (75.0) .390
Major complications 0.44+ 0.77 19 (44.2) 0.33+ 0.65 17 (32.7) .430
Minor complications 0.51+ 0.66 22 (51.2) 0.42+ 0.72 22 (42.3) .834
Complications—first 90 days postoperative
Total complications 1.19+ 1.28 51 (118.6) 1.04+ 1.28 54 (103.8) .577
Major complications 0.53+ 0.86 23 (53.5) 0.52+ 0.96 27 (51.9) .934
Minor complications 0.65+ 0.66 28 (65.1) 0.52+ 0.72 27 (51.9) .918
Complications—based on complication type
Cardiopulmonary 0.21+ 0.51 9 (20.9) 0.15+ 0.50 8 (15.4) .597
Dysphagia 0.19+ 0.50 8 (18.6) 0.06+ 0.24 3 (5.8) .103
Dysphonia 0 0 (0) 0.04+ 0.19 2 (3.8) .198
Electrolyte 0.02+ 0.15 1 (2.3) 0.02+ 0.14 1 (1.9) .893
Gastrointestinal 0 0 (0) 0.04+ 0.19 2 (3.8) .198
Infection 0.19+ 0.66 8 (18.6) 0.13+ 0.40 7 (13.5) .642
Instrumentation 0.07+ 0.26 3 (7.0) 0.02+ 0.14 1 (1.8) .226
Musculoskeletal 0 0 (0) 0 0 (0) —
Neurological 0.28+ 0.55 12 (27.9) 0.35+ 0.56 18 (34.6) .557
Operative 0.26+ 0.44 11 (25.6) 0.21+ 0.41 11 (21.2) .615
Organ failure 0 0 (0) 0.06+ 0.31 3 (5.8) .222
Other 0.02+ 0.15 1 (2.3) 0 0 (0) .274
Renal 0 0 (0) 0 0 (0) —
Vascular 0 0 (0) 0.04+ 0.19 2 (3.8) .198
Wound 0 0 (0) 0 0 (0) —
Radiographic 0.12+ 0.50 5 (11.6) 0.06+ 0.24 3 (5.8) .453
Abbreviations: BMP, patients receiving recombinant human bone morphogenetic protein–2 (rhBMP-2); NOBMP, patients not receiving rhBMP-2.
Table 4. Linear Regression Model Showing Relationship Between
Total Bone Morphogenetic Protein Dose and Complications.
Variables Adjusted R2 Pa
Number of fused levels 0.099 .012
Total complications 0.047 .065
Major complications 0.086 .019
Minor complications 0.009 .488
Reoperation complications 0.008 .235
Infections 0.01 .486
Instrumentation complications 0.019 .922
Neurologic complications 0.012 .544
Operative complications 0.066 .036
Dysphagia complications 0.001 .310
Dysphonia complications 0.013 .563
aBoldfaced P values indicate statistical significance.
Table 5. Logistic Regression Model for Complications.
Adjusted R2 Variables in Equation
Total complications <0.001 None
Major complications 0.326 Prior cervical surgery history
Number of prior cervical
surgeries
Number of prior anterior cervical
surgeries
Minor complications 0.122 Current smoking status
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undergoing longer fusions are more likely to receive BMP.26
To that end, it is crucial to define the rate of complications in
this high-risk patient population.
The number of participants enrolled in this trial compares
favorably to other investigations of BMP use in the cervical
spine.14,15,17 Additionally, we report data from a prospectively
gathered database that allows for detailed documentation of
complications and makes underreporting of complications less
likely. To our knowledge, this is the first prospective study to
report the effect of BMP in the cervical spine. This unique
strength allows us to perform a detailed analysis of complica-
tions. We showed, for example, that the average dose of BMP
(in cases where it was used) was 13.58 mg, or about 1.4 mg/
level. While the dosing of BMP is not reported consistently in
retrospective studies,17 this dose of BMP is lower than that
reported in previous trials.14,15 This reduction in BMP dosing
might explain the lack of complications seen in our patient
cohort. Several studies, for example, suggest that the adverse
effects related to BMP might be dose dependent.9,27 While our
analysis did reveal a significant but weak relationship between
the dose of BMP and the rate of major complications and
operative complications, this must be considered in the context
of an overall lower dose of BMP used.
The lower dose of BMP used in this cohort makes it impor-
tant to examine radiographic fusions and complications. How-
ever, we are limited by the relatively short follow-up period of
our patient cohort and therefore cannot report on fusion rates.
Fusion rates represent an important area of future investigation
because patients in this cohort are undergoing longer fusions
that cross the cervicothoracic junction and are therefore at
higher risk for pseudarthrosis. We are actively collecting lon-
ger term follow-up data in this prospectively enrolled cohort so
that we may be able to accurately report on fusion rates. While
the current article establishes the safety of posterior BMP use,
it will be important to establish its efficacy as well. There is
debate, however, about the length of time required to diag-
nose pseudarthrosis and the most effective way to identify
pseudarthrosis.28 Additionally, there is some debate within
the field about the significance of radiographic nonunions in
the setting of unchanged clinical outcomes and rates of
revision surgery.7,25
Despite these limitations, we believe our study has signifi-
cant value. We are able to show, through a variety of analyses,
that BMP may be used in the setting of adult cervical deformity
without an increase in short-term complications. This finding is
of value to adult cervical deformity surgeons considering BMP
use in patients.
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